The European Medicines Agency is exploring the feasibility of running two real-world evidence studies that could be of use to health technology assessment (HTA) bodies and payers as well as the agency in their respective areas of decision-making.
The first study will look at the natural history of multiple myeloma, while the second will focus on non-small cell...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?